REFERENCES
- Cazzola M, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89(5)357–362
- Jones P W, Bosh T K. Quality of life changes in COPD patients. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4)1283–1289
- Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001; 18(6)441–472
- Donohue J F, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1)47–55
- Ferguson G T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123(6)1817–1824
- Stockley R A, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61(2)122–128
- Dorinsky P M, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115(4)966–971
- Petty T L. The combination of ipratropium and albuterol is more effective than either agent alone. Chest 1995; 107(5 Suppl)183S–186S
- van Noord J A, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55(4)289–294
- Hanania N A, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124(3)834–843
- Calverley P M, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8)775–789
- Dorinsky P M, et al. Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy
- Casaburi R, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2)217–224
- Vincken W, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2)209–216
- O'Donnell D E, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23(6)832–840
- Make B, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005; 27(5)531–542
- Calverley P M, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58(10)855–860
- Mahler D A, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8)1084–1091
- Calverley P, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361(9356)449–456